Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

NATCO PHARMA LTD. - 524816 - Board Meeting Intimation for Notice Of Board Meeting Under SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

 NATCO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2022 ,inter alia, to consider and approve 1. To consider the Unaudited Financial Results for the quarter and nine months ended 31st December 2021 2. To consider third interim dividend, if any, for the financial year 2021-2022.
05-02-2022
Bigul

NATCO PHARMA LTD. - 524816 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Issue of Letter of Confirmation for duplicate share certificate
01-02-2022
Bigul

NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

 Allotment of 1,55,000 Equity Shares of Rs.2/- each under NATCO Employee Stock Option Scheme, 2017 (NATSOP 2017)
28-01-2022

Natco Pharma signs agreement with MPP to sell Molnupiravir capsules

 Natco Pharma Ltd on Thursday said it has signed a non-exclusive license agreement with the Medicines Patent Pool (MPP), Switzerland to manufacture and sell Molnupiravir capsules 200 mg for treatment of COVID-19. MPP had taken licence from Merck Sharp & Dohme Corp (MSD), USA for the same, the company said in a statement. Natco said with this licence agreement it can manufacture and sell Molnupiravir capsules 200 mg for Indian market, which will be sold under brand name MOLNUNAT for treatment of COVID-19 infection in patients who have high risk of progression of the disease including hospitalisation or death. It further said, "This agreement allows Natco to expand access to COVID-19 medicines in 105 countries in generic name. Under the licence, Natco can set its own price for the generic products it produces, paying a royalty on sales to MSD," the company said in a regulatory filing. However, MSD, Ridgeback Biotherapeutics and Emory University will not receive royalties for sales of
20-01-2022
Bigul

NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 NATCO announces License Agreement with the Medicines Patent Pool (MPP)
20-01-2022
Bigul

NATCO PHARMA LTD. - 524816 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Issue of new share certificate and loss of share certificate disclsoure
14-01-2022
Bigul

NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 NATCO Pharma Limited has been awarded Corporate Governance Award
07-01-2022
Bigul

NATCO PHARMA LTD. - 524816 - Statement Of Investor Complaints For The Quarter Ended December 2021

 No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- M ADINARAYANADesignation :- Company Secretary and Compliance Officer
05-01-2022
Bigul

NATCO PHARMA LTD. - 524816 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

 Compliance certificate for the quarter ended December 31, 2021
05-01-2022
Bigul

NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 NATCO completes acquisition of Dash Pharmaceuticals LLC
01-01-2022
Next Page
Close

Let's Open Free Demat Account